Clinical and experimental evidence supports that chronic oxidative stress is a primary contributing factor to numerous retinal degenerative diseases, such as age-related macular degeneration (AMD).
Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity
I suggest that melatonin therapy as pharmacologic agents and/or melatonin-rich foods, especially in AMD patients with measured low serum melatonin levels or high risk patients would be possibly an alternative approach to prevent and/or treat AMD.
Current evidence suggests that melatonin may act as a protective agent in ocular conditions such as photo-keratitis, cataract, glaucoma and retinopathy.
The majority had reduced pathologic macular changes. We conclude that the daily use of 3 mg melatonin seems to protect the retina and to delay macular degeneration. No significant side effects were observed…
“Within 6 months 90% of the trial participants had improved their AMD condition. The improvements continued until the trial ended at 24 months.”
Current research has revealed that the topical application of specific nutrients to the eyes can prevent and even reverse the progression of eye pressure and glaucoma severity for thousands of aging individuals.